



SEPTEMBER 12 – 15, 2026
SEOUL, REPUBLIC OF KOREA

Correspondence: Feng Yao (yaofeng@shsmu.edu.cn); Weijiao Xu (xuweijiao@sjtu.edu.cn); Zhaoxuan Wang (wang.zhaoxuan@outlook.com)

RESULTS

growth

C57BL/6 mice
LLC cells injection d0
Tumor size 150 mm³
d7 anti-osteopontin/iIgG2α, i.p. 20 μg, every three days
d7-d22 iMDK/DMSO, i.p. 9 mg/kg, every three days
d7-d22

Control
anti-osteopontin
iMDK
anti-osteopontin + iMDK

Tumour volumes (mm³)
Days after tumor inoculation

P < 0.0001
P < 0.0001
P < 0.0001